Evotec (EVO) Competitors

Evotec (NASDAQ:EVO) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Does the MarketBeat Community favor EVO or NUVL?

Nuvalent received 38 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 78.95% of users gave Nuvalent an outperform vote while only 53.85% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Evotec	Outperform Votes 7 53.85%	Underperform Votes 6 46.15%
Nuvalent	Outperform Votes 45 78.95%	Underperform Votes 12 21.05%

Is EVO or NUVL more profitable?

Evotec's return on equity of 0.00% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	N/A	N/A	N/A
Nuvalent	N/A	-28.63%	-27.15%

Do analysts recommend EVO or NUVL?

Evotec currently has a consensus price target of $5.93, indicating a potential upside of 35.81%. Nuvalent has a consensus price target of $115.50, indicating a potential upside of 53.67%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Does the media refer more to EVO or NUVL?

In the previous week, Nuvalent had 5 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Nuvalent and 1 mentions for Evotec. Nuvalent's average media sentiment score of 1.04 beat Evotec's score of 0.68 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Overall Sentiment
Evotec	Positive
Nuvalent	Positive

Which has stronger earnings & valuation, EVO or NUVL?

Evotec has higher revenue and earnings than Nuvalent.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$788.22M	1.97	-$90.82M	N/A	N/A
Nuvalent	N/A	N/A	-$126.22M	-$4.39	-17.12

Do insiders and institutionals believe in EVO or NUVL?

5.8% of Evotec shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 10.2% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, EVO or NUVL?

Evotec has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Summary

Nuvalent beats Evotec on 10 of the 15 factors compared between the two stocks.